Free Trial
NASDAQ:CELUW

Celularity (CELUW) Stock Price, News & Analysis

Celularity logo
$0.02
0.00 (0.00%)
(As of 11/1/2024 ET)

About Celularity Stock (NASDAQ:CELUW)

Key Stats

Today's Range
$0.0179
$0.0179
50-Day Range
$0.01
$0.02
52-Week Range
$0.00
$0.07
Volume
1 shs
Average Volume
28,425 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Receive CELUW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter.

CELUW Stock News Headlines

Celularity Provides Corporate Update
Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
Celularity Inc Ordinary Shares - Class A CELU
See More Headlines

CELUW Stock Analysis - Frequently Asked Questions

Celularity's stock was trading at $0.04 at the start of the year. Since then, CELUW stock has decreased by 55.3% and is now trading at $0.0179.
View the best growth stocks for 2024 here
.

Shares of CELUW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CELUW
Fax
N/A
Employees
220
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$33.52 million

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NASDAQ:CELUW) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners